Form 4: Tandem Diabetes CTO's Routine Stock Transactions

Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, reported routine acquisitions of common stock through restricted stock unit vesting and corresponding tax-related dispositions.

Summary

• Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care Inc. (TNDM), acquired 1,437 shares of common stock on August 15, 2025, through the vesting of Restricted Stock Units (RSUs) at a price of $0 per share.
• Concurrently, 730 shares were disposed of at $10.82 per share to satisfy tax withholding requirements related to this RSU vesting.
• Carpenter also acquired an additional 898 shares of common stock on August 15, 2025, through the vesting of another set of RSUs at a price of $0 per share.
• An additional 457 shares were disposed of at $10.82 per share to cover tax withholding obligations for this second RSU vesting.
• Following these reported transactions, Rick Carpenter beneficially owns 22,367 shares of Tandem Diabetes Care common stock.
• The RSUs were awarded under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.

Sentiment

Score: 7

Explanation: The filing indicates routine RSU vesting, which is a positive sign of executive retention and alignment with shareholder interests. The associated share dispositions are solely for tax withholding, not open market sales, which is a neutral event. Overall, it reflects stable and expected compensation practices.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the achievement of performance or tenure milestones, aligning executive incentives with shareholder interests.
• The transactions are routine RSU vestings, not open market sales, suggesting continued confidence in the company by the Chief Technology Officer.

Negatives

• Shares were disposed of to cover tax withholding, which is a common practice but reduces the direct shareholding of the reporting person.

Future Outlook

The vesting schedules for the Restricted Stock Units indicate future share issuances to the Chief Technology Officer in eight equal quarterly installments following the initial vesting dates of May 15, 2024, and May 15, 2025, respectively.

Industry Context

This routine insider transaction reflects standard executive compensation practices within the medical device and healthcare technology sectors, where equity awards like Restricted Stock Units are common tools for long-term incentive and retention.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation, with shares withheld for tax purposes upon vesting, is a standard practice across publicly traded companies, including peers in the diabetes care industry such as Dexcom (DXCM) and Insulet Corporation (PODD).
• These companies also frequently utilize equity-based incentives to align management interests with shareholder value creation.

Related Party Transactions

• Rick Carpenter, Chief Technology Officer, engaged in transactions involving the vesting of Restricted Stock Units and the disposition of shares to cover tax withholding, which are transactions between an officer and the company.

Stakeholder Impact

• Shareholders: The vesting of RSUs aligns the Chief Technology Officer's interests with long-term shareholder value. The disposition for tax purposes is a neutral event.
• Employees: The RSU awards and vesting demonstrate the company's commitment to executive compensation and retention strategies, potentially signaling stability within the leadership team.

Next Steps

• Remaining shares from the May 25, 2023 RSU award will vest in eight equal quarterly installments after May 15, 2024.
• Remaining shares from the May 23, 2024 RSU award will vest in eight equal quarterly installments after May 15, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax withholding). It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and reflect standard compensation practices, thus maintaining a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Rick Carpenter, Chief Technology Officer, Stock Transactions